Valdecoxib Pregnancy and Breastfeeding Warnings
Brand names: Bextra
Valdecoxib Pregnancy Warnings
Valdecoxib has been assigned to a pregnancy category C by the FDA. Animal studies have revealed evidence of teratogenicity. Data from human pregnancy studies are not available. Valdecoxib should only be given during pregnancy when benefit outweighs risk.
The manufacturer recommends that valdecoxib be avoided in late pregnancy (third trimester) due to the risk of premature closure of the ductus arteriosus.
Valdecoxib Breastfeeding Warnings
There are no data on the excretion of valdecoxib into human milk. Valdecoxib and its active metabolite are excreted in the milk of lactating rats. The manufacturer recommends that due to the potential for serious adverse reactions in nursing infants, a decision should be made to discontinue nursing or discontinue valdecoxib, taking into account the importance of the drug to the mother.
See also
References for pregnancy information
- Product Information. Bextra (valdecoxib). Pharmacia and Upjohn. 2001.
References for breastfeeding information
- Product Information. Bextra (valdecoxib). Pharmacia and Upjohn. 2001.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
